Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...
In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...
Zipalertinib showed a 35% overall response rate in EGFR exon 20 mutated NSCLC, with notable CNS activity and a favorable safety profile. NeoADAURA trial highlighted the feasibility of neoadjuvant EGFR ...
We are curing more cancers than we used to,” Cottrill said. “Recurrent cancers are more challenging to cure than cancers that ...
Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...
Brachytherapy, a form of internal radiotherapy, has emerged as a promising treatment modality for patients with non-small cell lung cancer (NSCLC). This technique involves the precise implantation of ...
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...
Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open. Olivia F. Lynch, MD, ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results